NCT05752877Unknown不适用
Clinical Study on Evaluation of Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T Cell Injection in Treatment of Advanced Glioma
Second Affiliated Hospital of Soochow University1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2021年5月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Objective Response Rate
研究概览
简要总结
The goal of this clinical trial is to estimate the safety, tolerance and initial efficacy of target IL-13Rα2 or B7-H3 UCAR-T cell injection in the treatment of patients with advanced glioma, as well as the pharmacokinetic characteristics of its metabolites after single and multiple administrations and the biomarkers related to efficacy, safety and drug metabolism.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-70 years old, male or female, and the expected survival period is not less than 3 months.
- •Advanced, locally advanced or recurrent tumor diagnosed histologically or cytologically.
- •Failed in previous standard treatment or gived up treatment for various reasons after failure of first-line treatment.
- •Failed in therapy by PD-1 or PD-L1 antibody or stopped administration of PD-1 or PD-L1 antibody for more than 4 weeks.
- •At least 1 measurable target lesion (RECIST v1.1).
- •0-2 in ECOG physical state score.
- •Available initial or recurrent tumor tissue for at least 10 stanable and detectable sections.
- •Blood routine test: WBC ≥ 3×10^9/L, lymphocyte percentage (LY%) ≥ 15%, hemoglobin Hbo (Hb) ≥ 90g/L, platelet (PLT) ≥ 60×10^9/L.
- •Liver and kidney functions: alanine transaminase (ALT) and aspartate transaminase (AST) < 3 times of the normal value, total bilirubin (TBiL) < 1.5 times of the normal value, serum creatinine (SCR) < 1.5 times of the normal value.
- •IL-13Rα2 or B7-H3 antigen expression > 50%.
- •Volunteered to enroll this study and signed the informed consent with good compliance and cooperation with follow-up.
- •Experienced radiotherapy and chemotherapy with an interval of more than 4 week.
排除标准
- •Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood HBV DNA titer ≥ 5 × 10^2 copies/L; HCV antibody and peripheral blood HCV RNA positive; Human immunodeficiency virus (HIV) antibody positive; CMV DNA test positive; Syphilis test positive.
- •Experienced any gene therapy previously.
- •Needing long-term immunosuppressants for any reason.
- •Any serious and uncontrolled systemic autoimmune disease or any unstable systemic disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease and temporal arteritis.
- •Severe heart, lung, liver and kidney insufficiency or severe debilitating lung disease; Cardiac function: Grade III or above according to NYHA standard; Liver function: grade C in Child-Puge grading standard; Renal function: chronic kidney disease (CKD) more than stage 4; Renal insufficiency above stage Ⅲ; Lung function: symptoms of severe respiratory failure, involving other organs; Brain function: abnormality of central nervous system or disturbance of consciousness.
- •Administrating of systematical steroids currently (except usage inhaled steroids recently or currently).
- •Pregnancy and lactation (the safety of this treatment for unborn children is not clear, and female participants with reproductive potential must have negative serum or urine pregnancy test within 48 hours before administration).
- •Allergy to immunotherapy and related drugs.
- •Complicated with another tumor.
- •History of organ transplantation or waiting for organ transplantation.
- •After evaluation by researcher,noncompliance with the requirements of the study protocol was confirmed.
结局指标
主要结局
Objective Response Rate
时间窗: Up to 5 years or complete the follow-up of the last enrolled patient, whichever comes first.
The proportion of patients whose tumor size decreases to the expected value and can continue to meet the expected minimum time limit。
次要结局
- Progression-Free Survival(Up to 5 years or complete the follow-up of the last enrolled patient, whichever comes first.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Clinical Trial to Evaluate Ultrasonic Surgical Device in Chronic Pressure UlcerWoundNecrosisPressure UlcerNCT02007824Seoul National University Hospital30
招募中
2 期
The Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Major Depressive DisorderTreatment Resistant DepressionDepressionNCT04805879University of Calgary80
招募中
1 期
Study of Panobinostat (LBH589) in Patients With Sickle Cell DiseaseSickle Cell DiseaseNCT01245179Abdullah Kutlar18
已完成
1 期
A Study Evulating DA-302168S Tablets in Overweight/Obese SubjectsOverweight and ObesityNCT06541730Chendu DIAO Pharmaceutical Group CO., LTD.48
已完成
2 期
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's DiseaseAlzheimer Disease (AD)NCT03518073Eli Lilly and Company360